用于肺上皮细胞和免疫细胞的鼻内mRNA递送的硫脂纳米颗粒。

IF 9.6
Yuqin Men, David O Popoola, Zhi Cao, Yiran Li, Stephan Wilkens, Yong Teng, Qinghe Meng, Marc Hershenson, Yamin Li
{"title":"用于肺上皮细胞和免疫细胞的鼻内mRNA递送的硫脂纳米颗粒。","authors":"Yuqin Men, David O Popoola, Zhi Cao, Yiran Li, Stephan Wilkens, Yong Teng, Qinghe Meng, Marc Hershenson, Yamin Li","doi":"10.1016/j.actbio.2025.08.032","DOIUrl":null,"url":null,"abstract":"<p><p>Lung epithelial and immune cells play an important role in respiratory health, serving as the first line of defense. Targeting these cells presents significant therapeutic opportunities, particularly for mRNA-based medicine. However, efficient mRNA delivery to lung cells remains challenging due to mucosal barriers, enzymatic degradation, and complex tissue architecture. In this study, we developed sulfonium lipid nanoparticles (sLNPs) featuring a sulfonium head group and branched tail structure. These sLNPs efficiently delivered mRNA to lung epithelial and immune cells via intranasal instillation in mice, transfecting club cells, ciliated cells, and macrophages, which are key players in lung structure and function. Additionally, sLNPs successfully delivered CRISPR-Cas9 mRNA and sgRNA for genome editing, as well as cytokine mRNA for immune modulation in the lungs. The sLNP platform demonstrated safety in adult mice, with no significant local or systemic tissue damage observed. These findings highlight the sLNP platform's effectiveness and versatility in delivering diverse mRNA molecules, demonstrating its potential for applications ranging from gene editing to immunomodulation therapies. With further optimization, the sLNP system could pave the way for advanced mRNA-based treatments for lung diseases. STATEMENT OF SIGNIFICANCE: Almost all of the previously developed lipids for pulmonary mRNA delivery are amine-based. We designed and synthesized a group of lipids featuring the sulfonium charge-carrying group for mRNA delivery. This is the first demonstration of employing sulfonium lipid nanoparticles (sLNPs) for mRNA delivery to lung epithelial and immune cells in vivo. These sLNPs enabled efficient pulmonary delivery of diverse mRNA cargos, supporting applications such as bioluminescence imaging, gene editing, and immunomodulation. Club and ciliated cells as well as macrophages in the bronchoalveolar fluid, were successfully transfected. No sustained inflammation or toxicity was induced, highlighting the safety of these sulfonium lipid materials.</p>","PeriodicalId":93848,"journal":{"name":"Acta biomaterialia","volume":" ","pages":""},"PeriodicalIF":9.6000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sulfonium lipid nanoparticles for intranasal mRNA delivery to lung epithelial and immune cells.\",\"authors\":\"Yuqin Men, David O Popoola, Zhi Cao, Yiran Li, Stephan Wilkens, Yong Teng, Qinghe Meng, Marc Hershenson, Yamin Li\",\"doi\":\"10.1016/j.actbio.2025.08.032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lung epithelial and immune cells play an important role in respiratory health, serving as the first line of defense. Targeting these cells presents significant therapeutic opportunities, particularly for mRNA-based medicine. However, efficient mRNA delivery to lung cells remains challenging due to mucosal barriers, enzymatic degradation, and complex tissue architecture. In this study, we developed sulfonium lipid nanoparticles (sLNPs) featuring a sulfonium head group and branched tail structure. These sLNPs efficiently delivered mRNA to lung epithelial and immune cells via intranasal instillation in mice, transfecting club cells, ciliated cells, and macrophages, which are key players in lung structure and function. Additionally, sLNPs successfully delivered CRISPR-Cas9 mRNA and sgRNA for genome editing, as well as cytokine mRNA for immune modulation in the lungs. The sLNP platform demonstrated safety in adult mice, with no significant local or systemic tissue damage observed. These findings highlight the sLNP platform's effectiveness and versatility in delivering diverse mRNA molecules, demonstrating its potential for applications ranging from gene editing to immunomodulation therapies. With further optimization, the sLNP system could pave the way for advanced mRNA-based treatments for lung diseases. STATEMENT OF SIGNIFICANCE: Almost all of the previously developed lipids for pulmonary mRNA delivery are amine-based. We designed and synthesized a group of lipids featuring the sulfonium charge-carrying group for mRNA delivery. This is the first demonstration of employing sulfonium lipid nanoparticles (sLNPs) for mRNA delivery to lung epithelial and immune cells in vivo. These sLNPs enabled efficient pulmonary delivery of diverse mRNA cargos, supporting applications such as bioluminescence imaging, gene editing, and immunomodulation. Club and ciliated cells as well as macrophages in the bronchoalveolar fluid, were successfully transfected. No sustained inflammation or toxicity was induced, highlighting the safety of these sulfonium lipid materials.</p>\",\"PeriodicalId\":93848,\"journal\":{\"name\":\"Acta biomaterialia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta biomaterialia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.actbio.2025.08.032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta biomaterialia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.actbio.2025.08.032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

肺上皮细胞和免疫细胞作为第一道防线,在呼吸系统健康中起着重要作用。靶向这些细胞提供了重要的治疗机会,特别是基于mrna的药物。然而,由于粘膜屏障、酶降解和复杂的组织结构,有效的mRNA递送到肺细胞仍然具有挑战性。在这项研究中,我们开发了具有磺胺头基和分支尾结构的脂质磺酸纳米颗粒(sLNPs)。这些sLNPs通过小鼠鼻内灌注,转染俱乐部细胞、纤毛细胞和巨噬细胞,有效地将mRNA传递到肺上皮细胞和免疫细胞,这些细胞是肺结构和功能的关键参与者。此外,sLNPs成功递送用于基因组编辑的CRISPR-Cas9 mRNA和sgRNA,以及用于肺免疫调节的细胞因子mRNA。sLNP平台在成年小鼠中证明是安全的,没有观察到明显的局部或全身组织损伤。这些发现突出了sLNP平台在传递不同mRNA分子方面的有效性和多功能性,展示了其从基因编辑到免疫调节治疗的应用潜力。随着进一步的优化,sLNP系统可以为基于mrna的高级肺部疾病治疗铺平道路。意义声明:几乎所有先前开发的用于肺mRNA传递的脂质都是胺基的。我们设计并合成了一组具有磺胺载电基团的脂质,用于mRNA的传递。这是首次在体内使用脂质磺酸纳米颗粒(sLNPs)将mRNA递送到肺上皮细胞和免疫细胞。这些sLNPs能够有效地将各种mRNA货物输送到肺部,支持生物发光成像、基因编辑和免疫调节等应用。成功转染了支气管肺泡液中的俱乐部细胞和纤毛细胞以及巨噬细胞。没有引起持续的炎症或毒性,强调了这些磺胺脂质材料的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sulfonium lipid nanoparticles for intranasal mRNA delivery to lung epithelial and immune cells.

Lung epithelial and immune cells play an important role in respiratory health, serving as the first line of defense. Targeting these cells presents significant therapeutic opportunities, particularly for mRNA-based medicine. However, efficient mRNA delivery to lung cells remains challenging due to mucosal barriers, enzymatic degradation, and complex tissue architecture. In this study, we developed sulfonium lipid nanoparticles (sLNPs) featuring a sulfonium head group and branched tail structure. These sLNPs efficiently delivered mRNA to lung epithelial and immune cells via intranasal instillation in mice, transfecting club cells, ciliated cells, and macrophages, which are key players in lung structure and function. Additionally, sLNPs successfully delivered CRISPR-Cas9 mRNA and sgRNA for genome editing, as well as cytokine mRNA for immune modulation in the lungs. The sLNP platform demonstrated safety in adult mice, with no significant local or systemic tissue damage observed. These findings highlight the sLNP platform's effectiveness and versatility in delivering diverse mRNA molecules, demonstrating its potential for applications ranging from gene editing to immunomodulation therapies. With further optimization, the sLNP system could pave the way for advanced mRNA-based treatments for lung diseases. STATEMENT OF SIGNIFICANCE: Almost all of the previously developed lipids for pulmonary mRNA delivery are amine-based. We designed and synthesized a group of lipids featuring the sulfonium charge-carrying group for mRNA delivery. This is the first demonstration of employing sulfonium lipid nanoparticles (sLNPs) for mRNA delivery to lung epithelial and immune cells in vivo. These sLNPs enabled efficient pulmonary delivery of diverse mRNA cargos, supporting applications such as bioluminescence imaging, gene editing, and immunomodulation. Club and ciliated cells as well as macrophages in the bronchoalveolar fluid, were successfully transfected. No sustained inflammation or toxicity was induced, highlighting the safety of these sulfonium lipid materials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信